Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | November 08, 2013

The Hottest Topics and Technologies in Interventional Cardiology at TCT 2013

By Dave Fornell, DAIC editor

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting brought many new insights about the latest cardiovascular technologies and treatment techniques. Among the hottest topics were transcatheter heart valve repairs, renal denervation to treat drug resistant hypertension, left atrial appendage (LAA) occluders to prevent stroke and eliminate warfarin therapy in atrial fibrillation patients, bifurcation stenting trials and techniques, new insights on anti-clotting agents, increasing use of ultrasound and intravascular imaging, new technologies for FFR lesion assessments, and the latest stent trial data.

I offer my editor’s choice for the most innovative new technologies presented in sessions and on the show floor in a video format.

For a video of the top meeting highlights, Herb Aronow, M.D., offers his views on some of the most interesting topics discussed in sessions.

The most exciting interventional device to enter the U.S. market a couple days prior to TCT was Abbott's MitraClip. We conducted a video interview with the lead author of the MitraClip FDA pivotal trial at TCT.

Here is a summary of some of the top news from TCT. You can click on any item to read the full story.

CoreValve shows outcomes as good or better that Sapien

CT-FFR shown to be comparable to invasive FFR

Dedicated Tryton bifurcation stent did not meet primary endpoint

Provisional vs. two-stent bifurcation therapy has similar outcomes

Data promising for first FDA drug-eluting balloon trial

Simplified, non-adenosine iFR compares favorably with standard FFR

Hypothermia for STEMI safe, but did not reduce infarct size

Thrombectomy does not improve outcomes in NSTEMI PCI

MitraClip trial data leads to FDA approvalVideo interview with lead author of study

Bioresorbable polymer coated stent equal to traditional DES

Boston Scientific’s Lotus TAVR valve meets primary endpoints in REPRISE II

Pre-hospital bivalirudin for STEMI improves outcomes

• Data from two trials (ARCTIC-INTERRUPTION and OPTIMIZE) shows short-duration DAPT is feasible

Genetic profiling for CYP2C19 antiplatelet agents improves outcomes

Transradial access lowers bleeding risks in women

In addition to these news items, listed below are more top trial summaries and new product releases.

Related Content

AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
News | Left Atrial Appendage (LAA) Occluders | August 28, 2019
AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling...
Boston Scientific Initiates OPTION Trial of Watchman FLX
News | Left Atrial Appendage (LAA) Occluders | June 12, 2019
Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-generation...
Watchman FLX in Clinical Trial at MedStar Heart and Vascular Institute
News | Left Atrial Appendage (LAA) Occluders | June 26, 2018
MedStar Heart & Vascular Institute physicians participating in a clinical trial have become the first in the Mid-...
A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman LAA Occluder device in an echo image. #HRS2018

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman device in an echo image.

Feature | Left Atrial Appendage (LAA) Occluders | May 18, 2018
May 18, 2018 — Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism f
AtriCure Launches AtriClip FLEX•V Device in the United States
Technology | Left Atrial Appendage (LAA) Occluders | February 22, 2018
February 22, 2018 — AtriCure Inc.
J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib
News | Left Atrial Appendage (LAA) Occluders | January 18, 2018
January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide